RegeneRx To Develop RGN-457 For Cystic Fibrosis
Oct 3rd 2008Drug InformationCystic Fibrosis
Regenerx Biopharmaceuticals, INC. (AMEX:RGN) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis (CF). RGN-457 is based on thymosin beta 4 (Tβ4) peptide formulated as an inhaled therapeutic agent to address this patient population. CF is a life-threatening, hereditary disease that impairs the patient’s ability to breathe due to the accumulation of thick and sticky mucus secretions in the airways of the lungs.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
